Obesity-associated hypertension: new insights into mechanisms.

Obesity is strongly associated with hypertension and cardiovascular disease. Several central and peripheral abnormalities that can explain the development or maintenance of high arterial pressure in obesity have been identified. These include activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system. Obesity is also associated with endothelial dysfunction and renal functional abnormalities that may play a role in the development of hypertension. The continuing discovery of mechanisms regulating appetite and metabolism is likely to lead to new therapies for obesity-induced hypertension. Better understanding of leptin signaling in the hypothalamus and the mechanisms of leptin resistance should facilitate therapeutic approaches to reverse the phenomenon of selective leptin resistance. Other hunger and satiety signals such as ghrelin and peptide YY are potentially attractive therapeutic strategies for treatment of obesity and its complications. These recent discoveries should lead to novel strategies for treatment of obesity and hypertension.

[1]  H. Münzberg,et al.  Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. , 2004, Endocrinology.

[2]  D. Randall,et al.  Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[3]  A. Mark,et al.  Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. , 2004, The Journal of clinical investigation.

[4]  M. Gollasch,et al.  Visceral Periadventitial Adipose Tissue Regulates Arterial Tone of Mesenteric Arteries , 2004, Hypertension.

[5]  M. Lombardi,et al.  Visceral Fat in Hypertension: Influence on Insulin Resistance and β-Cell Function , 2004, Hypertension.

[6]  A. Baron,et al.  Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. , 2004, Diabetes.

[7]  Arya M. Sharma.  Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension? , 2004, Hypertension.

[8]  A. Yoshimura,et al.  Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity , 2004, Nature Medicine.

[9]  J. Flier,et al.  Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3 , 2004, Nature Medicine.

[10]  Donald D Hensrud,et al.  Splanchnic lipolysis in human obesity. , 2004, The Journal of clinical investigation.

[11]  T. Ogihara,et al.  Hypoadiponectinemia Is an Independent Risk Factor for Hypertension , 2004, Hypertension.

[12]  A. A. da Silva,et al.  Role of Hypothalamic Melanocortin 3/4-Receptors in Mediating Chronic Cardiovascular, Renal, and Metabolic Actions of Leptin , 2004, Hypertension.

[13]  G. Yancopoulos,et al.  Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Rocchini,et al.  Hypertension and Insulin Resistance Are Not Directly Related in Obese Dogs , 2004, Hypertension.

[15]  M. Iida,et al.  Ghrelin Acts at the Nucleus of the Solitary Tract to Decrease Arterial Pressure in Rats , 2004, Hypertension.

[16]  A. Marciniak,et al.  Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. , 2004, Life sciences.

[17]  R. Ahima,et al.  Adiponectin acts in the brain to decrease body weight , 2004, Nature Medicine.

[18]  M. Birnbaum,et al.  AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus , 2004, Nature.

[19]  T. Goodfriend,et al.  Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. , 2004, Hypertension.

[20]  A. A. da Silva,et al.  Role of Endothelin-1 in Blood Pressure Regulation in a Rat Model of Visceral Obesity and Hypertension , 2004, Hypertension.

[21]  B. Egan,et al.  Epoxy-Keto Derivative of Linoleic Acid Stimulates Aldosterone Secretion , 2004, Hypertension.

[22]  A. Mark,et al.  Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. , 2004, American journal of physiology. Endocrinology and metabolism.

[23]  J. Flier.  Obesity Wars Molecular Progress Confronts an Expanding Epidemic , 2004, Cell.

[24]  A. A. da Silva,et al.  Aldosterone Antagonism Attenuates Obesity-Induced Hypertension and Glomerular Hyperfiltration , 2004, Hypertension.

[25]  A. Dobrian,et al.  Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced Obesity , 2004, Hypertension.

[26]  J. Panza,et al.  Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. , 2003, Hypertension.

[27]  R. Unger.  The physiology of cellular liporegulation. , 2003, Annual review of physiology.

[28]  W. Scherbaum,et al.  Human adipocytes secrete mineralocorticoid-releasing factors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Kauma,et al.  Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. , 2003, Diabetes.

[30]  A. Dorrance,et al.  Downregulation of Renal CYP-Derived Eicosanoid Synthesis in Rats With Diet-Induced Hypertension , 2003, Hypertension.

[31]  R. Dampney,et al.  Cardiovascular Responses Evoked by Leptin Acting on Neurons in the Ventromedial and Dorsomedial Hypothalamus , 2003, Hypertension.

[32]  Mohammad A Ghatei,et al.  Inhibition of food intake in obese subjects by peptide YY3-36. , 2003, The New England journal of medicine.

[33]  A. Mark,et al.  Role of Melanocortin-4 Receptors in Mediating Renal Sympathoactivation to Leptin and Insulin , 2003, The Journal of Neuroscience.

[34]  J. Flier,et al.  Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. , 2003, The Journal of clinical investigation.

[35]  M. Esler,et al.  Interactions Between Leptin and the Human Sympathetic Nervous System , 2003, Hypertension.

[36]  John E Hall,et al.  The kidney, hypertension, and obesity. , 2003, Hypertension.

[37]  A. Mark,et al.  Intracellular Mechanisms Involved in Leptin Regulation of Sympathetic Outflow , 2003, Hypertension.

[38]  Alexander S. Banks,et al.  STAT3 signalling is required for leptin regulation of energy balance but not reproduction , 2003, Nature.

[39]  Michael Esterman,et al.  The Distribution and Mechanism of Action of Ghrelin in the CNS Demonstrates a Novel Hypothalamic Circuit Regulating Energy Homeostasis , 2003, Neuron.

[40]  M. Schwartz,et al.  Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities , 2003, Frontiers in Neuroendocrinology.

[41]  S. Beske,et al.  Sympathetic Neural Activation in Visceral Obesity , 2002, Circulation.

[42]  J. Ermolieff,et al.  Protein tyrosine phosphatase 1B inhibitors for diabetes , 2002, Nature Reviews Drug Discovery.

[43]  M. Schwartz,et al.  Elevated plasma ghrelin levels in Prader–Willi syndrome , 2002, Nature Medicine.

[44]  B. Kennedy,et al.  Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. , 2002, Developmental cell.

[45]  Young-Bum Kim,et al.  PTP1B regulates leptin signal transduction in vivo. , 2002, Developmental cell.

[46]  A. Mark,et al.  Selective Resistance to Central Neural Administration of Leptin in Agouti Obese Mice , 2002, Hypertension.

[47]  John E. Hall,et al.  Chronic Cardiovascular and Renal Actions of Leptin: Role of Adrenergic Activity , 2002, Hypertension.

[48]  A. Fukamizu,et al.  Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  MarioVaz,et al.  Regional Sympathetic Nervous Activity and Oxygen Consumption in Obese Normotensive Human Subjects , 1997 .